Oxidative Stress in Chronic Liver Disease: Relationship Between Peripheral and Hepatic Measurements

Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202-2859, USA.
The American Journal of the Medical Sciences (Impact Factor: 1.39). 06/2011; 342(4):314-7. DOI: 10.1097/MAJ.0b013e31821d9905
Source: PubMed


Oxidative stress plays an important role in the pathogenesis of many liver diseases. Investigators often measure markers of oxidative stress in peripheral veins as a reflection of hepatic oxidative stress as it is not always feasible to measure oxidative stress in liver tissue. However, it is unknown whether markers of oxidative stress measured from peripheral sites accurately reflect hepatic tissue oxidative stress. The aim of this study is to examine the relationship of oxidative stress marker among hepatic tissue, hepatic and peripheral veins and urine.
Malondialdehyde (MDA), a marker of oxidative stress was measured in hepatic vein, peripheral vein and urine samples from 26 consecutive patients undergoing transjugular liver procedures. In 19 patients undergoing liver biopsies, we measured MDA by immunohistochemical staining of paraffin-embedded liver tissue.
Peripheral venous MDA levels showed significant correlation with hepatic venous MDA levels (r = 0.62, P = 0.02), but they did not correlate with hepatic tissue MDA content (r = 0.22, P = 0.4). Hepatic venous MDA levels did not correlate with hepatic tissue MDA content (r = -0.01, P = 0.9). Subgroup analysis of patients without portal hypertension showed a positive correlation between hepatic venous and hepatic tissue MDA levels, but this was not statistically significant (r = 0.45, P = 0.22). Urinary MDA did not correlate with MDA from any other sampling location.
Oxidative stress measured from the peripheral venous samples is poorly reflective of hepatic tissue oxidative stress. Hepatic venous sampling might be suitable for assessing hepatic tissue oxidative stress in patients without portal hypertension, but a larger study is needed to examine this possibility.

Download full-text


Available from: Raj Vuppalanchi, Apr 02, 2014
  • Source
    • "All these motivating findings have focused recent clinical research on the utilization of the xanthine oxidase inhibitors allopurinol and oxypurinol in the prevention of cardiovascular disorders. Different studies of the inhibitory effects of xanthine have revealed that, inhibition of xanthine oxidase significantly reduced the levels of oxidative stress in the circulation in individuals with heart failure (Doehner et al., 2002), diabetes (Desco et al., 2002), metabolic syndrome (Yiginer et al., 2008), obstructive sleep apnea (El Solh et al., 2006), coronary artery disease (Eskurza et al., 2006), and liver disease (Vuppalanchi et al., 2011). Furthermore, blood pressure was improved in hypertensive individuals in response to xanthine oxidase inhibition (Feig et al., 2008). "

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effects of estrogen (E2) on systemic and splanchnic hyperdynamic circulation in portal hypertensive rats. Fifty castrated female Sprague-Dawley rats were divided into five groups: sham operation (SO), partial portal vein ligation (PPVL) + placebo (PLAC), PPVL + E2, PPVL + ICI and PPVL + E2 + ICI. Hemodynamic measurements were performed using ultrasonography. Mesenteric arteriole contractility in response to norepinephrine was determined using a vessel perfusion system. Oxidative stress in the mesenteric artery was investigated by in situ detection of the superoxide anion (O2•(-)) and hydrogen peroxide (H2O2) concentrations. Treatment with E2 resulted in a significant decrease of portal pressure (P < 0.01) and portal venous inflow (P < 0.05), and higher systemic vascular resistance (P < 0.05) and splanchnic arteriolar resistance (P < 0.01) in PPVL + E2 rats compared to PPVL + PLAC rats. In the mesenteric arterioles of PPVL + E2 rats, the dose-response curve was shifted left, and the EC50 was decreased (P < 0.01). E2 reduced O2•(-) production and H2O2 concentration in the mesenteric artery. However, ICI182, 780 reversed the beneficial effects of E2, therefore, the systemic and splanchnic hyperdynamic circulation were more deteriorated in ICI182, 780-treated rats. Treatment with estrogen improved the systemic and splanchnic hyperdynamic circulation in PPVL rats, in part due to the alleviation of oxidative stress.
    World Journal of Gastroenterology 10/2013; 19(40):6863-8. DOI:10.3748/wjg.v19.i40.6863 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present studies intended to investigate the protective effects of melatonin (5mg/kg bw, fed orally) against adrenaline (0.25mg/kg of body weight, s.c. for a period of 15 days) induced oxidative stress in rat liver and heart through certain antioxidative indices like Cu-Zn superoxide dismutase (Cu-Zn SOD), Mn superoxide dismutase (Mn SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), reduced glutathione (GSH) and lipid peroxidation (LPO), other biochemical parameters such as mitochondrial Kreb's cycle enzymes as well as respiratory chain enzymes were also measured. Antioxidative enzymes and other parameters showed a significant reduction while LPO, Mn SOD and reduced glutathione levels increased significantly in adrenaline-treated rats as compared to control groups. These biochemical changes were supported through our studies on tissue morphology. However, all these parameters were protected from being altered when rats were pre-treated with melatonin. The present studies perhaps for the first time comprehensively indicated that melatonin has the potential to provide protection against adrenaline-induced tissue injury and further strengthen the notion that this indole may be relevant therapeu-tically in future days in humans exposed to various stressful situations. INTRODUCTION Melatonin (N-acetyl-5-methoxy tryptamine, CAS number: 73-31-4), a tryptophan derivative, was first isolated from bovine pineal gland and was structurally identified in 1958
    Journal of Pharmacy Research 01/2014; · 2.89 Impact Factor
Show more